#JPM2026 Day Three Update
The 44th annual J.P. Morgan Healthcare Conference continued to deliver pivotal updates on Day Three, with major announcements across biopharma, biotech, and gene therapy. Our latest report captures the key takeaways from presentations by leading companies, providing actionable insights for BD&L teams, portfolio strategists, and investors.
What’s Inside
- Mega Cap: AbbVie outlined its strategy to offset Humira LOE with Skyrizi and Rinvoq momentum, projecting $31B combined sales by 2027, alongside neuroscience and oncology pipeline expansion.
- Large Cap: UCB showcased innovation-driven growth with Bimzelx and a diversified pipeline in neurology and immunology, supported by strong 2025 financial performance.
- Mid Cap: Arcus Biosciences emphasized its late-stage oncology assets and a pivot toward immunology, while Disc Medicine detailed commercial readiness for bitopertin in EPP.
- Small Cap: 4D Molecular Therapeutics advanced toward Phase III milestones in retinal diseases; Agios expanded its PK activation franchise into thalassemia and sickle cell disease.
- Micro Cap: Larimar and Neurogene highlighted progress toward accelerated approvals in rare genetic disorders, reinforcing momentum in precision medicine.
Get the complete analysis of Day 3 presentations, including detailed company profiles, pipeline updates, and commercial outlooks.
